![](/wp-content/uploads/2018/10/XpIQzCUBQYiC6OIY0Qlm.png)
$599
Would AZ, Teva, or Mylan/Upjohn Buy Sanofi’s DCV Business?
Earlier this week, Sanofi hosted its 2019 Capital Markets Day and the company disclosed plans to re-structure its diabetes and cardiovascular business. As part of the discussion, senior management entertained the idea that it would consider divesting the business and/or its assets if it found the right suitor. Below, FENIX provides analysis of companies who could potentially be interested in Sanofi’s DCV assets and why AstraZeneca, Teva, or even Viatris (Mylan/Upjohn) could be viable options.